Stem Cell Transplant Clinical Trials & Research

Memorial Sloan Kettering’s team approach to transplantation goes beyond the bedside to research in the laboratory. Our investigators have experience in matching people with the right clinical trials that will help them the most.

We have been developing and evaluating promising new ways to do transplants for decades. We created many of the methods that help people who need transplants today. Choosing to have a transplant at MSK may give you access to new treatments before they’re widely available elsewhere.

Our clinical and laboratory researchers are working together to learn more about how healthy immune reactions work and how these can go wrong in people with cancer. We are using that information to be able to offer the latest treatment advances to people who have their transplants at MSK.

Our doctors are leading a large number of clinical trials to test new ways to do stem cell transplants. These research studies are based on our growing understanding of the immune system. Our research is increasingly translational, which means that discoveries made in the lab are taken directly to our patients.

Areas of research include studies of the immune cells called T cells and the role that they play in transplants. In addition, we are look for strategies to reduce complications such as graft-versus-host disease and ways to lower the toxicity of the treatments given before transplants. We are also trying to expand the use of stem cell transplants to treat more diseases.

Learn more about the clinical trials we are currently conducting:

and/or
Reset
14 Clinical Trials found
A Phase 1 Study of TRX103 in People With Blood Cancers Receiving a Donated Stem Cell Transplant
Graft-versus-host disease (GVHD) is a serious condition that can happen after a stem cell transplant from a donor. The donated cells see the healthy tissues in the recipient's body as foreign and attack them. TRX103 is a new drug designed to reduce the risk of GVHD.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1-2 Study of Belumosudil in Children and Adolescents With Chronic Graft-Versus-Host Disease
Chronic graft-versus-host disease (cGVHD) is a condition in which healthy transplanted stem cells attack the recipient's healthy cells. cGVHD most often happens more than 100 days after a stem cell transplant, but it can happen at any time.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study Assessing Treatment for Inflammation Before a Stem Cell Transplant in People with Immune and Autoinflammatory Conditions
Primary immune regulatory disorder (PIRD) and autoinflammatory conditions are conditions of the immune system that can cause an unusual amount of inflammation. While a stem cell transplant is a standard treatment for people with a PIRD or autoinflammatory condition, the inflammation caused by these conditions can reduce the effectiveness of this treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Axatilimab Plus Ruxolitinib in Adults and Children With Chronic Graft-Versus-Host Disease
Researchers want to see if a steroid-free approach using ruxolitinib, with or without axatilimab, works well to treat cGVHD. Ruxolitinib blocks JAK proteins, which may reduce inflammation (swelling) and immune system reactions related to GVHD. Axatilimab blocks a protein called CSF-1R that controls white blood cells which play a role in GVHD.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Belumosudil After a Stem Cell Transplant to Prevent Graft-Versus-Host Disease
After a stem cell transplant, some patients develop a condition called graft-versus-host disease (GVHD). This occurs when the donor's healthy immune cells see the recipient's normal cells as foreign and begin to attack them.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Belumosudil in People With Chronic Graft vs. Host Disease
After a stem cell transplant, a condition called chronic graft-versus-host disease (cGVHD) can occur. The new donor immune cells (like T cells and B cells) attack the recipient's healthy tissues, thinking they are foreign. It usually starts around 100 days after the transplant, but it can begin earlier or later.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Isatuximab to Treat Low Blood Cell Counts in People With Blood Cancer Who Had a Stem Cell Transplant from a Donor
Researchers want to see if isatuximab helps improve immune cytopenias (ICs) caused by a donated stem cell transplant. A transplant from a donor is called an allogeneic hematopoietic cell transplant (allo-HCT). People with blood cancers often receive an allo-HCT. ICs are abnormally low blood cell counts that can happen after an allo-HCT. They cause people to need blood or platelet transfusions. Platelets are blood cells needed for clotting. Researchers in this study will see if isatuximab can improve ICs and lessen the need for blood or platelet transfusions.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 3 Study Comparing Ruxolitinib/Tacrolimus/Methotrexate with Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil to Prevent Graft-Versus-Host Disease After a Stem Cell Transplant
After a stem cell transplant, some patients develop a condition called graft-versus-host disease (GVHD). This occurs when the donor's healthy immune cells see the recipient's normal cells as foreign and attack them.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase II Study of Bone Marrow Transplantation for Newly Diagnosed People with Severe Aplastic Anemia
Severe aplastic anemia is a serious condition where the bone marrow does not make the normal amount of blood cells. Bone marrow transplantation is one way to treat this disease. It has been reserved for people under age 40 with a related donor whose cells fully match theirs. However, advances have been made in bone marrow transplantation that make it an option for more people.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase II Study of Photobiomodulation Therapy in Children and Adults with Oral Graft-versus-Host Disease after Stem Cell Transplantation
The purpose of this study is to assess the safety and effectiveness of a specialized light treatment for children and adults with chronic graft-versus host disease (GVHD) of the mouth (oral GVHD) that has not improved after standard treatment. GVHD is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body and cause serious health problems. Oral GVHD can cause mouth inflammation, pain, and sores.
New York City, Commack, Basking Ridge, Skin Cancer Center Hauppauge, Westchester, Monmouth, Bergen, Nassau